Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Rezolute (Nasdaq: RZLT) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. Management will hold one-on-one investor meetings during the conference. Investors should contact their Guggenheim representative to schedule meetings.

News Market Reaction – RZLT

-7.62%

4 alerts

-7.62% News Effect

-3.8% Trough Tracked

-$22M Valuation Impact

$270M Market Cap

0.5x Rel. Volume

On the day this news was published, RZLT declined 7.62%, reflecting a notable negative market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $270M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: February 11–12, 2026

1 metrics

Conference dates February 11–12, 2026 Guggenheim Emerging Outlook: Biotech Summit 2026

Market Reality Check

Price: $2.69 Vol: Volume 1,964,353 vs 20-da...

low vol

$2.69 Last Close

Volume Volume 1,964,353 vs 20-day average 4,150,695 (0.47x typical activity) low

Technical Price $3.15 trading below 200-day MA at $5.94, reflecting a longer downtrend

Peers on Argus

RZLT fell 2.78% while several biotech peers (RIGL, KALV, RLAY, TBPH) showed gain...

RZLT fell 2.78% while several biotech peers (RIGL, KALV, RLAY, TBPH) showed gains and VIR was slightly down, indicating stock-specific pressure rather than a broad sector move.

Historical Context

5 past events · Latest: Jan 07 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Clinical trial update	Negative	+23.0%	Further sunRIZE data and EAP outcomes after missed endpoints.
Dec 11	Phase 3 topline	Negative	-87.2%	sunRIZE Phase 3 failed primary and key secondary endpoints.
Nov 10	Equity inducement grant	Neutral	-7.5%	Inducement stock options granted to new employees.
Nov 06	Earnings and update	Positive	+2.7%	Fiscal Q1 2026 results and confirmation of Phase 3 timelines.
Nov 05	Investor event	Neutral	+5.1%	Announcement of virtual investor event on ersodetug program.

Pattern Detected

News tied to major clinical readouts has produced large, sometimes opposite, price swings, while routine corporate or conference updates have seen smaller, mixed reactions.

Recent Company History

Over the past several months, Rezolute has been driven mainly by its ersodetug clinical program. The Dec 11, 2025 sunRIZE Phase 3 miss led to an -87.2% move, while a deeper sunRIZE/EAP update on Jan 7, 2026 saw a rebound of 23.04%. Earlier, an earnings update on Nov 6, 2025 with cash of $152.2M and ongoing trial plans produced a modest gain. Conference and inducement-grant announcements in early November showed smaller, mixed price reactions compared with the large swings on pivotal data.

Market Pulse Summary

The stock moved -7.6% in the session following this news. A negative reaction despite a routine conf...

Analysis

The stock moved -7.6% in the session following this news. A negative reaction despite a routine conference announcement fits a pattern where non-fundamental news sometimes coincided with downside moves. Past trading showed the stock reacting much more sharply to major clinical outcomes, including the sunRIZE Phase 3 miss, than to investor-relations events. Any outsized decline relative to a neutral conference update would need to be viewed within this context of prior volatility and the stock’s position below longer-term moving averages.

Key Terms

hyperinsulinism (HI), hypoglycemia

2 terms

hyperinsulinism (HI) medical

"focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI)"

Hyperinsulinism (HI) is a medical condition where the body produces too much insulin, the hormone that lowers blood sugar, causing dangerously low glucose levels. For investors, HI matters because it drives demand for diagnostics, treatments, and long‑term care solutions; like a thermostat stuck too low, it creates a predictable market need for therapies and monitoring devices that companies may supply. Clinical advances or approvals can materially affect the value of related healthcare firms.

hypoglycemia medical

"focused on treating hypoglycemia caused by all forms of hyperinsulinism"

Hypoglycemia is a condition where blood sugar falls too low to fuel the body and brain, causing symptoms like shakiness, confusion, sweating or fainting. Think of it as a car running low on gas: systems slow or fail until fuel is restored. Investors care because treatments, devices or drugs that cause or prevent hypoglycemia affect patient safety, regulatory approval, product labeling and market acceptance, which influence a company’s commercial prospects.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

When will Rezolute (RZLT) participate in the Guggenheim Emerging Outlook: Biotech Summit 2026?

Rezolute management will attend the summit on February 11-12, 2026. According to Rezolute, management will be in New York for the Guggenheim Emerging Outlook: Biotech Summit and will hold one-on-one investor meetings throughout the two-day event to engage with shareholders and analysts.

What opportunities will Rezolute (RZLT) provide investors at the February 2026 Guggenheim biotech summit?

Investors can request one-on-one meetings with Rezolute management during the conference. According to Rezolute, these meetings are arranged through Guggenheim representatives and offer direct access to management for questions on strategy, programs, and corporate updates.

How can investors schedule a meeting with Rezolute (RZLT) at the Guggenheim Emerging Outlook: Biotech Summit?

Investors should contact their Guggenheim representative to arrange meetings with Rezolute management. According to Rezolute, Guggenheim handles scheduling for the February 11-12, 2026 summit, so investor requests should be routed through their Guggenheim contact.

Where is the Guggenheim Emerging Outlook: Biotech Summit 2026 where Rezolute (RZLT) will appear?

The summit will take place in New York on February 11-12, 2026. According to Rezolute, management will attend the New York event and participate in scheduled one-on-one investor meetings organized by Guggenheim representatives.

Will Rezolute (RZLT) host a public presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Rezolute announced management will participate and hold one-on-one investor meetings, but did not specify a public presentation. According to Rezolute, engagement at the February 11-12, 2026 summit will focus on scheduled investor meetings arranged through Guggenheim.